Point-of-care testing can achieve same-day diagnosis for infants and rapid ART initiation: results from government programmes across six African countries.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
03 2021
Historique:
revised: 15 01 2021
received: 17 09 2020
accepted: 27 01 2021
entrez: 21 3 2021
pubmed: 22 3 2021
medline: 18 9 2021
Statut: ppublish

Résumé

Point-of-care (POC) early infant diagnosis (EID) testing has been shown to dramatically decrease turnaround times from sample collection to caregiver result receipt and time to ART initiation for HIV-positive infants compared to centralized laboratory testing. As governments in sub-Saharan Africa implement POC EID technologies, we report on the feasibility and effectiveness of POC EID testing and the impact of same-day result delivery on rapid ART initiation within national programmes across six countries. This pre-/post-evaluation compared centralized laboratory-based (pre) with POC (post) EID testing in 52 facilities across Cameroon, Democratic Republic of Congo, Ethiopia, Kenya, Senegal and Zimbabwe between April 2017 and October 2019 (country-dependent). Data were collected retrospectively from routine records at health facilities for all infants tested under two years of age. Hazard ratios and 95% confidence intervals were calculated to compare time-to-event outcomes, visualized with Kaplan-Meier curves, and the Somers' D test was used to compare continuous outcomes. Data were collected for 2892 EID tests conducted on centralized laboratory-based platforms and 4610 EID tests on POC devices with 127 (4%) and 192 (4%) HIV-positive infants identified, respectively. POC EID significantly reduced the time from sample collection to caregiver result receipt (POC median: 0 days, IQR: 0 to 0 vs. centralized: 35 days, IQR: 26 to 56) and time from sample collection to ART initiation for HIV-positive infants (POC median: 1 day, IQR: 0 to 7 vs. centralized: 39 days, IQR: 26 to 57). With POC testing, 72% of infants received results on the same day as sample collection; HIV-positive infants with a same-day diagnosis had six times the rate of ART initiation compared to those diagnosed one or more days after sample collection (HR: 6.39; 95% CI: 3.44 to 11.85). Same-day diagnosis and treatment initiation for infants is possible with POC EID within routine government-led and -supported public sector healthcare facilities in resource-limited settings. Given that POC EID allows for rapid ART initiation, aligning to the World Health Organization's recommendation of ART initiation within seven days, its use in public sector programmes has the potential to reduce overall mortality for infants with HIV through early treatment initiation.

Identifiants

pubmed: 33745234
doi: 10.1002/jia2.25677
pmc: PMC7981587
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25677

Informations de copyright

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

PLoS One. 2020 Oct 9;15(10):e0240621
pubmed: 33035274
Lancet HIV. 2016 Nov;3(11):e539-e548
pubmed: 27658873
J Acquir Immune Defic Syndr. 2020 Jul 1;84 Suppl 1:S41-S48
pubmed: 32520914
AIDS. 2018 Jul 17;32(11):1453-1463
pubmed: 29746301
PLoS Med. 2011 Jul;8(7):e1001056
pubmed: 21811403
PLoS One. 2018 Mar 2;13(3):e0193577
pubmed: 29499042
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
Stat Methods Med Res. 2020 Nov;29(11):3424-3454
pubmed: 32466712
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e1-4
pubmed: 24933096
J Acquir Immune Defic Syndr. 2020 Jul 1;84 Suppl 1:S12-S21
pubmed: 32520910
J Acquir Immune Defic Syndr. 2020 Jul 1;84 Suppl 1:S5-S11
pubmed: 32520909
Clin Infect Dis. 2018 Aug 16;67(5):701-707
pubmed: 29490026
AIDS. 2021 Feb 2;35(2):287-297
pubmed: 33394672
Lancet HIV. 2019 Mar;6(3):e182-e190
pubmed: 30737187
PLoS One. 2019 Jun 27;14(6):e0218369
pubmed: 31246963
J Acquir Immune Defic Syndr. 2020 Jul 1;84 Suppl 1:S70-S77
pubmed: 32520918
Lancet HIV. 2019 Jun;6(6):e373-e381
pubmed: 30987937

Auteurs

Caroline E Boeke (CE)

Clinton Health Access Initiative, Boston, MA, USA.

Jessica Joseph (J)

Clinton Health Access Initiative, Boston, MA, USA.

Melody Wang (M)

Clinton Health Access Initiative, Boston, MA, USA.

Zelalem M Abate (ZM)

Clinton Health Access Initiative, Addis Ababa, Ethiopia.

Charles Atem (C)

Clinton Health Access Initiative, Yaoundé, Cameroon.

Khady Diatou Coulibaly (KD)

Division de la Lutte Contre le SIDA et les IST, Ministère de la Santé et de l'Action Sociale, Dakar, Senegal.

Adisu Kebede (A)

Ethiopian Public Health Institute, Addis Ababa, Ethiopia.

Brianán Kiernan (B)

Clinton Health Access Initiative, Dakar, Senegal.

Leonard Kingwara (L)

National HIV Reference Lab, Nairobi, Kenya.
National AIDS and STI Control Programme (NASCOP), Nairobi, Kenya.

Phibeon Mangwendeza (P)

Clinton Health Access Initiative, Harare, Zimbabwe.

Tatenda Maparo (T)

Clinton Health Access Initiative, Harare, Zimbabwe.

Rose Nadege Mbaye (RN)

Clinton Health Access Initiative, Dakar, Senegal.

Solomon Mukungunugwa (S)

Ministry of Health and Child Care, Harare, Zimbabwe.

Catherine Ngugi (C)

National AIDS and STI Control Programme (NASCOP), Nairobi, Kenya.

Divine Nzuobontane (D)

Clinton Health Access Initiative, Yaoundé, Cameroon.

Marie Claire Okomo Assoumou (MC)

National Public Health Laboratory, Yaoundé, Cameroon.

Yemsirach Reta (Y)

Ethiopian Public Health Institute, Addis Ababa, Ethiopia.

Barbara Wambugu (B)

National AIDS and STI Control Programme (NASCOP), Nairobi, Kenya.

Maria R Rioja (MR)

Clinton Health Access Initiative, Boston, MA, USA.

Trevor Peter (T)

Clinton Health Access Initiative, Boston, MA, USA.

Naoko Doi (N)

Clinton Health Access Initiative, Boston, MA, USA.

Lara Vojnov (L)

Clinton Health Access Initiative, Boston, MA, USA.

Shaukat Khan (S)

Clinton Health Access Initiative, Boston, MA, USA.

Jilian A Sacks (JA)

Clinton Health Access Initiative, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH